MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.7% – Still a Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was up 0.7% during mid-day trading on Wednesday . The company traded as high as $1.48 and last traded at $1.39. Approximately 648,116 shares were traded during trading, a decline of 37% from the average daily volume of 1,028,490 shares. The stock had previously closed at $1.38.

MAIA Biotechnology Stock Performance

The firm’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.56. The stock has a market capitalization of $85.73 million, a price-to-earnings ratio of -2.10 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. Analysts forecast that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current year.

Insider Transactions at MAIA Biotechnology

In other news, Director Stan Smith purchased 75,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were bought at an average cost of $1.34 per share, for a total transaction of $100,500.00. Following the completion of the acquisition, the director directly owned 1,519,178 shares in the company, valued at approximately $2,035,698.52. This trade represents a 5.19% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vlad Vitoc acquired 72,700 shares of MAIA Biotechnology stock in a transaction dated Monday, June 1st. The shares were purchased at an average cost of $1.39 per share, with a total value of $101,053.00. Following the completion of the transaction, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at $1,356,808.19. This trade represents a 8.05% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 149,700 shares of company stock valued at $204,233. Corporate insiders own 19.81% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares during the last quarter. Centric Wealth Management lifted its position in shares of MAIA Biotechnology by 2.0% in the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares in the last quarter. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the second quarter worth $29,000. Ritholtz Wealth Management bought a new position in MAIA Biotechnology in the fourth quarter valued at $35,000. Finally, Jane Street Group LLC bought a new position in MAIA Biotechnology in the second quarter valued at $52,000. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.